Quinolines as Chemotherapeutic Agents for Leishmaniasis

Author(s): Kristie A. Reynolds, Wendy A. Loughlin, David J. Young

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 13 , Issue 5 , 2013

Become EABM
Become Reviewer


The development of leishmanicidal quinolines and their in vitro (promastigote and amastigote) and, where applicable, in vivo activities are reviewed. This survey provides a direct comparison of bioactivity across different species (e.g. L. donovani, L. amazonensis, L. chagasi, L infantum), and in different animal models (e.g. L. donovani Balb/c mice and L. donovani infected hamsters). The progress of selected quinolines through pre-clinical development and phase I/II trials, and the lead quinoline drugs sitamaquinine and Imiquimod, are discussed in conjunction with delivery systems and combination therapies.

Keywords: Leishmaniasis, quinolines, affordable chemotherapies

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 12 March, 2013
Page: [730 - 743]
Pages: 14
DOI: 10.2174/1389557511313050010
Price: $65

Article Metrics

PDF: 26